Page 41 - 2019_06-Haematologica-web

Thrombopoietin receptor agonists in ITP
74. Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169 (1):111-116.
75. Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R. Response loss and development of neutralizing antibodies dur- ing long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Eur J Haematol. 2016;97(1):101- 103.
76. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442-452.e1.
77. Zhang X, Chuai Y, Nie W, Wang A, Dai G. Thrombopoietin receptor agonists for pre- vention and treatment of chemotherapy- induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev. 2017;11:CD012035.
78. Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inher- ited thrombocytopenia deriving from MYH9 mutations. Blood. 2010;116(26): 5832-5837.
79. Gerrits AJ, Leven EA, Frelinger AL 3rd, et al. Effects of eltrombopag on platelet count and
platelet activation in Wiskott-Aldrich syn- drome/X-linked thrombocytopenia. Blood. 2015;126(11):1367-1378.
80. Rodeghiero F, Pecci A, Balduini CL. Thrombopoietin receptor agonists in hered- itary thrombocytopenias. J Thromb Haemost. 2018;16(9):1700-1710.
81. Bussel JB, Kuter DJ, Aledort LM, et al. A ran- domized trial of avatrombopag, an investi- gational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocy- topenia. Blood. 2014;123(25):3887-3894.
82. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombo- cytopenia. Br J Haematol. 2018;183(3):479- 490.
83. Kong Z, Qin P, Xiao S, et al. A novel recom- binant human thrombopoietin therapy for the management of immune thrombocy- topenia in pregnancy. Blood. 2017;130(9): 1097-1103.
topenia: Results of two phase 3, random- ized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.
86. Robak T, Jarque I, Musteata V, et al. Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis. Blood. 2017;130(Suppl 1):15.
87. Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci Transl Med. 2017;9(414).
88. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, random- ized Phase III clinical trial. Int J Hematol. 2011;94(1):71-80.
89. Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previ- ously treated chronic immune thrombocy- topenia. J Thromb Haemost. 2012;10(5):799-
84. Huang Y, Liu X, Xue F, et al. [Efficacy and
safety of rhTPO in the treatment of pediatric
primary immune thrombocytopenia]. 806.
Zhonghua Xue Ye Xue Za Zhi. 2015;36(6):
511-514.
85. Bussel J, Arnold DM, Grossbard E, et al.
Fostamatinib for the treatment of adult per- sistent and chronic immune thrombocy-
90. Janssens A, Tarantino M, Bird RJ, et al. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. Acta Haematol. 2015;134(4):215-228.
haematologica | 2019; 104(6)
1123